In summary, the clinical potential of CAR-M therapy is becoming evident, while targeting key nodes in macrophage polarization—such as Furin, PAD4, and PGAM5—and their combination with existing therapies like PD-1 inhibitors are opening new avenues for enhancing anti-tumor immune responses. The gene discussed is PGAM5; the disease is neoplasm.